These results are reassuring for management of both underweight and overweight patients with AF.

That said, I would still have reservations about prescribing DOACs in the small minority of patients with BMI >45 kg/m2 or body weight >330lbs due to their underrepresentation in the pivotal trials and when you look at the supplementary data you will see a weight of 262 was 95% tile so >330 would be around the 99th %tile of weight.


https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066279